Genmab A/S (NASDAQ:GMAB) Shares Acquired by Ingalls & Snyder LLC

Ingalls & Snyder LLC lifted its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 29.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 229,700 shares of the company's stock after purchasing an additional 52,117 shares during the period. Ingalls & Snyder LLC's holdings in Genmab A/S were worth $5,772,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC acquired a new stake in Genmab A/S in the 4th quarter valued at $393,000. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Genmab A/S in the fourth quarter valued at about $216,000. M&T Bank Corp increased its stake in shares of Genmab A/S by 87.8% during the fourth quarter. M&T Bank Corp now owns 15,432 shares of the company's stock worth $492,000 after purchasing an additional 7,213 shares in the last quarter. Vestmark Advisory Solutions Inc. raised its position in shares of Genmab A/S by 28.5% during the 4th quarter. Vestmark Advisory Solutions Inc. now owns 35,656 shares of the company's stock worth $1,135,000 after purchasing an additional 7,905 shares during the last quarter. Finally, Principal Securities Inc. purchased a new position in Genmab A/S in the 4th quarter valued at about $77,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Trading Down 0.0 %

Genmab A/S stock traded down $0.01 during mid-day trading on Friday, hitting $27.80. The company's stock had a trading volume of 347,187 shares, compared to its average volume of 545,344. The stock's fifty day moving average is $26.85 and its two-hundred day moving average is $28.16. The firm has a market capitalization of $18.38 billion, a PE ratio of 23.17, a price-to-earnings-growth ratio of 0.88 and a beta of 0.97. Genmab A/S has a 1 year low of $24.53 and a 1 year high of $39.53.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The business had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. On average, equities analysts expect that Genmab A/S will post 1.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on GMAB shares. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Genmab A/S in a report on Tuesday, August 20th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Tuesday, August 27th. Truist Financial upped their target price on shares of Genmab A/S from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Tuesday, June 4th. Royal Bank of Canada upgraded shares of Genmab A/S from a "sector perform" rating to an "outperform" rating in a research report on Monday, July 15th. Finally, BTIG Research boosted their price target on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday, June 27th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Genmab A/S presently has a consensus rating of "Hold" and an average price target of $49.50.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.